Q2 2025 saw 12% revenue growth and 41% higher adjusted EBITDA, led by strong human health and consumer health segments. Operational leverage, cost reallocation, and product innovation drove margin gains, while a $15 million impairment was taken on the protein plant due to tariff uncertainty.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.